ROLVEDON Biologic Drug Snags FDA Patent Extension
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for ROLVEDON, a medicine that helps people, so its patent can be extended. This means the company behind ROLVEDON gets more time to protect their invention and keep making money before others can copy it. If you’re in the business of making or selling medicines, this update affects when new versions can enter the market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
ROLVEDON Patent Extension Determined
The FDA has determined the regulatory review period for ROLVEDON to support an application to the U.S. Patent and Trademark Office for a patent extension on this human biological product. This lets the patent holder seek more time to protect the invention and continue exclusive sales before others can copy it.
Competition Delay for ROLVEDON
The FDA notice affects companies that make or sell medicines because setting the regulatory review period is part of the process that can delay when new versions or competitors may enter the market for ROLVEDON. If you are in the business of making or selling medicines, this update changes the timing of potential market entry for competing products.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19350, Nonclinical Testing Terminology
The FDA is updating its rules to replace the words “animal” tests with “nonclinical” tests, making room for new, smarter ways to check drug safety without relying only on animal testing. This change affects drug makers and researchers but won’t add new costs or requirements. The rule kicks in on February 4, 2027, and comments are open until December 7, 2026.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
Previous / Next Documents
Previous: 2025-11040, Determination of Regulatory Review Period for Purposes of Patent Extension; RIVFLOZA
The FDA has set the official review period for RIVFLOZA, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for when RIVFLOZA stays exclusive and when competition can start.
Next: 2025-11042, Submission for OMB Review; Comment Request; Reinstatement
The USDA is bringing back the Local Food Marketing Practices Survey to keep track of how local foods are grown and sold. This helps farmers, shoppers, and policymakers make smart choices about local food. If you have thoughts, you’ve got until July 16, 2025, to share them—no cost, just your voice!